From: Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer
Patients, n | 80 |
---|---|
Age at MDT (years), median (range) | 72 (50–87) |
Initial tumor stage, n (%) | |
 T1 | 3 (3.8%) |
 T2 | 21 (26.3%) |
 T3 | 54 (67.5%) |
 Unknown | 2 (2.5) |
Initial nodal stage, n (%) | |
 N0 | 51 (63.7%) |
 N +  | 21 (26.3%) |
 Nx | 5 (6.3%) |
 Unknown | 3 (3.8%) |
Gleason score, n (%) | |
 ≤ 6 | 1 (1.3%) |
 7 | 26 (32.5%) |
 8 | 13 (16,3%) |
 ≥ 9 | 40 (50.0%) |
Initial PSA (ng/ml), median (range) | 11,7 (3,6–1252) |
Primary treatment, n (%) | |
 Surgery | 39 (48.8%) |
 Surgery + postoperative RT | 25 (31.3%) |
 Definitive RT | 4 (5.0%) |
 Primary ADT or chemotherapy | 9 (11.3%) |
 No pretreatment | 3 (3.8%) |
Time from primary treatment to MDT (months), median (range) | 22.1 (0–260) |
Category of oligometastatic disease, n (%) | |
 De novo synchronous oligometastatic disease | 25 (31.3%) |
 Metachronous oligorecurrent disease | 37 (46.3%) |
 Metachronous oligoprogressive disease | 3 (3.8%) |
 Induced oligometastatic disease | 7 (8.8%) |
 Repeat oligometastatic disease | 8 (10.0%) |
Previous ADT, n (%) | 43 (53.8%) |
HSPC/CRPC, n (%) | 62 (77.5%)/18 (22.5%) |